Juan Jesús
Cruz Hernández
Profesor Emérito
Hospital Ramón y Cajal
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (20)
2023
-
Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk
Cells, Vol. 12, Núm. 15
-
Telomere Length as a New Risk Marker of Early-Onset Colorectal Cancer
International Journal of Molecular Sciences, Vol. 24, Núm. 4
2021
-
Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020) (Clinical and Translational Oncology, (2021), 23, 5, (913-921), 10.1007/s12094-020-02533-1)
Clinical and Translational Oncology
-
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications
JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169
2019
-
Working towards a consensus on the oncological approach of breakthrough pain: A Delphi survey of Spanish experts
Journal of Pain Research, Vol. 12, pp. 2349-2358
2018
-
Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii612
-
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice
Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 862-869
-
Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study
Clinical and Translational Oncology, Vol. 20, Núm. 5, pp. 613-618
-
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
British Journal of Cancer, Vol. 119, Núm. 9, pp. 1052-1059
-
The quality oncology practice initiative program: Experience in Spain
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii570-viii571
2017
-
GEIS-21: A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS)
British Journal of Cancer, Vol. 117, Núm. 6, pp. 767-774
-
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: A multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)
Annals of Oncology, Vol. 28, Núm. 12, pp. 2994-2999
-
Should clinically meaningful outcomes in cancer be based on individual survival rather than median overall survival?
Journal of Comparative Effectiveness Research, Vol. 6, Núm. 6, pp. 491-495
2016
-
Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology
Advances in Therapy, Vol. 33, Núm. 11, pp. 2059-2068
-
Quality indicators to assure and improve cancer care in Spain using the delphi technique
JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558
2015
-
Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population
Patient Preference and Adherence, Vol. 10
2014
-
Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists
Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 914-920
2013
-
SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs)
Clinical and Translational Oncology, Vol. 15, Núm. 1, pp. 20-25
2012
-
Spanish Society of Medical Oncology (SEOM) Cancer and Thrombosis Working Group
Clinical and Translational Oncology
2010
-
Consensus document on the use of biosimilar granulocyte-colony stimulating factor for the correction of neutropenia associated in cancer patients
Farmacia Hospitalaria, Vol. 34, Núm. SUPPL. 1, pp. 45-50